Ipsen unveils name change for UK-based life sciences company

Ipsen Biopharm, the UK-based affiliate of the Ipsen group, has revealed that it has changed the name of its life sciences company from Syntaxin to Ipsen Bioinnovation.

The firm acquired Syntaxin back in July 2013, in a bid to enhance its presence in the field of toxins, and to explore the discovery and development of new compounds in the area of recombinant botulinum toxins.

A leader in this field, the Abingdon-based life sciences company has expertise in natural and modified recombinant botulinum toxins, as well as targeted secretion inhibitors.

Dr John Chaddock, Ipsen Bioinnovation’s vice-president Neurology, commented: "We’re delighted to announce our new name, Ipsen Bioinnovation. It reinforces Ipsen’s leadership position as we continue to develop a highly differentiated and innovative toxin platform.”

Claude Bertrand, Ipsen’s executive vice-president, research and development and chief scientific officer, added that the name change successfully completed the integration process of Syntaxin into Ipsen.

He believes the move consolidates the merged firm's position in the UK and global toxin marketplace.